Trial reportJournal of traumatic stress2020
Posttraumatic Growth After MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder.
Trial report in Journal of traumatic stress, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It carries an expression of concern. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review.Psychopharmacology · 2022Pooled it
- Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.Psychopharmacology · 2020Trial
- The Relationship Between Traumatic Growth and Meaning of Life in Nursing Students.Nursing open · 2026Article
- Lifetime MDMA use and associations with meaning in life in the context of childhood trauma.Scientific reports · 2026Article
- Interventional Psychiatry and Emerging Treatments for Posttraumatic Stress Disorder (PTSD): A Systematic Review.Psychiatry and clinical psychopharmacology · 2025Article
- Moderating factors in psilocybin-assisted treatment affecting mood and personality: A naturalistic, open-label investigation.Psychopharmacology · 2025Article
- Is there a place for psychedelics in sports practice?Acta neuropsychiatrica · 2025Review
- Active inference and psychodynamics: a novel integration with applications to depression and stress disorders.Frontiers in psychiatry · 2025Article
- Novel psychedelic interventions for post-traumatic stress disorder and their promise for precision medicine.Therapeutic advances in psychopharmacology · 2025Review
- The Psychedelic Future of Post-Traumatic Stress Disorder Treatment.Current neuropharmacology · 2024Review
- Treatment of Posttraumatic Stress Disorder: A State-of-the-art Review.Current neuropharmacology · 2024Review
- Exploring the subjective experience of rave party participants in Israel who consume psychedelic drugs: a qualitative inquiry.Harm reduction journal · 2023Article
- The Therapeutic Potential of Amphetamine-like Psychostimulants.Life (Basel, Switzerland) · 2023Review
- Longitudinal and transcultural assessment of the relationship between hallucinogens, well-being, and post-traumatic growth during the COVID-19 pandemic.Scientific reports · 2023Article
- Therapeutic role of psilocybin and 3,4-methylenedioxymethamphetamine in trauma: A literature review.World journal of psychiatry · 2023Review
- Psychoactive Drugs in the Management of Post Traumatic Stress Disorder: A Promising New Horizon.Cureus · 2022Review
- Facing death, returning to life: A qualitative analysis of MDMA-assisted therapy for anxiety associated with life-threatening illness.Frontiers in psychiatry · 2022Article
- Current Perspective on the Therapeutic Preset for Substance-Assisted Psychotherapy.Frontiers in psychology · 2021Review
- Relational and Growth Outcomes Following Couples Therapy With MDMA for PTSD.Frontiers in psychiatry · 2021Article
Corrections and comments
- Erratum issued
- Expression of concern
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
3,4-Methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for posttraumatic stress disorder (PTSD) has been shown to significantly reduce clinical symptomatology, but posttraumatic growth (PTG), which consists of positive changes in self-perception, interpersonal relationships, or philosophy of life, has not been studied with this treatment. Participant data (n = 60) were pooled from three Phase 2 clinical studies employing triple-blind crossover designs. Participants were required to meet DSM-IV-R criteria for PTSD with a score higher than 50 on the Clinician-Administered PTSD Scale (CAPS-IV) as well as previous inadequate response to pharmacological and/or psychotherapeutic treatment. Data were aggregated into two groups: an active MDMA dose group (75-125 mg of MDMA; n = 45) or placebo/active control (0-40 mg of MDMA; n = 15). Measures included the Posttraumatic Growth Inventory (PTGI) and the CAPS-IV, which were administered at baseline, primary endpoint, treatment exit, and 12-month follow-up. At primary endpoint, the MDMA group demonstrated more PTG, Hedges' g = 1.14, 95% CI [0.49, 1.78], p < .001; and a larger reduction in PTSD symptom severity, Hedges' g = 0.88, 95% CI [-0.28, 1.50], p < .001, relative to the control group. Relative to baseline, at the 12-month follow-up, within-subject PTG was higher, p < .001; PTSD symptom severity scores were lower, p < .001; and two-thirds of participants (67.2%) no longer met criteria for PTSD. MDMA-assisted psychotherapy for PTSD resulted in PTG and clinical symptom reductions of large-magnitude effect sizes. Results suggest that PTG may provide a new mechanism of action warranting further study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.